Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : DA-1241,Sitagliptin Phosphate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
NeuroBo Reports Positive DA-1241 Safety Data and Opens Enrollment for Phase 2a
Details : DA-1241, a GPR119 agonist, is in Phase 2 trials with sitagliptin, a DPP4 inhibitor, for steatohepatitis treatment.
Brand Name : DA-1241
Molecule Type : Small molecule
Upfront Cash : Not Applicable
January 18, 2024
Lead Product(s) : DA-1241,Sitagliptin Phosphate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Cosmos Health
Deal Size : Undisclosed
Deal Type : Acquisition
Cosmos Health Enters into Definitive Agreement to Acquire Type-2 Diabetes Treatment DIABIT-IS X
Details : Through the acquisition, Cosmos will gain the license and rights for DIABIT-IS X, a drug that contains the active substance sitagliptin and is used in the treatment of type-2 diabetes.
Brand Name : DIABIT-IS X
Molecule Type : Small molecule
Upfront Cash : Undisclosed
December 20, 2023
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Cosmos Health
Deal Size : Undisclosed
Deal Type : Acquisition
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Receives USFDA Approval for ZITUVIO™ to Treat Adult Patients with Type 2 Diabetes Mellitus
Details : Zituvio (Sitagliptin) tablets A is a dipeptidyl peptidase-4 (DPP-4) inhibitor indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
Brand Name : Zituvio
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 20, 2023
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sitagliptin Phosphate,Pioglitazone,Metformin
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Akums Gets DCGI Nod for Triple Combination Diabetes Medication
Details : Sitagliptin, Pioglitazone & Metformin are combined for the treatment of diabetes. Metformin, coupled with the functional and corrective influence of pioglitazone on beta-cell and metabolic syndrome and the stability of Sitagliptin, make an effective solu...
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 27, 2023
Lead Product(s) : Sitagliptin Phosphate,Pioglitazone,Metformin
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Phase II
Sponsor : CUREator
Deal Size : $1.0 million
Deal Type : Financing
Details : GMRx4 is being developed to provide a synergistic effect from three best-in-class type 2 diabetes treatments – metformin, dapagliflozin and sitagliptin – and, in an ultra-low-dose, single pill formulation, aims to be a more effective, simpler and saf...
Brand Name : GMRx4
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 20, 2022
Lead Product(s) : Metformin,Dapagliflozin,Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Phase II
Sponsor : CUREator
Deal Size : $1.0 million
Deal Type : Financing
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Not Applicable
Deal Type : Not Applicable
Generics of MSD Diabetes Pill Set to Flood Market as Patent Expires
Details : Januvia (sitagliptin), a class of dipeptidyl peptidase (DPP4) inhibitors, is used with a proper diet and exercise program and possibly with other medications to control high blood sugar.
Brand Name : Januvia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2022
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Sun Pharmaceutical Industries Limited
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zent2U Announces Successful Pivotal BE Trial on Sitagliptin Development
Details : Sitagliptin is a DPP-4 inhibitor, which is believed to exert its actions in patients with type 2 diabetes by slowing the inactivation of incretin hormones.
Brand Name : Sitagliptin-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 12, 2021
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Codexis and Merck Amend and Extend Supply Agreement for Enzyme Used in Manufacture of Sitagliptin
Details : Under a research and development agreement, Codexis and Merck leveraged Codexis’ CodeEvolver® enzyme engineering platform technology to design a novel, proprietary enzyme to serve as a biocatalyst in the sitagliptin manufacturing process.
Brand Name : Januvia
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 09, 2021
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Merck & Co
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Zydus Cadila Arm Receives US FDA Approval for Sitagliptin Base
Details : Zydus’ Sitagliptin base contains the active moiety sitagliptin in a different form than used in the branded reference product, Januvia (sitagliptin phosphate).
Brand Name : Januvia
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 06, 2021
Lead Product(s) : Sitagliptin Phosphate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?